- Biome Australia (BIO) publishes successful acne clinical trial data confirming the efficacy of the company’s targeted probiotic approach to acne treatment
- Results from the clinical trial undertaken in Italy showed the use of the company’s probiotic treatment led to a 31.1 per cent reduction in acne lesions over four weeks
- Following the success of the clinical trial, the company says it is preparing to launch and manufacture a new product for acne treatment called Biome Acne Probiotic
- Biome Acne Probiotic will become available to over 2300 community pharmacies and independent health practitioners across Australia, and will also be launched into the UK and New Zealand markets as “Biome Derma”
- In afternoon trade, shares were trading up 5 per cent at 10 cents
Biome Australia (BIO) has published successful acne clinical trial data confirming the efficacy of the company’s targeted probiotic approach to acne treatment.
Results from the clinical trial undertaken in Italy showed the use of the company’s probiotic treatment led to a 31.1 per cent reduction in acne lesions over four weeks.
In addition, the company reported that patients saw an average 38.9 per cent reduction in acne lesions over 8 weeks.
Following the success of the clinical trial, the company said it is preparing to launch and manufacture a new product for acne treatment called Biome Acne Probiotic.
With the support of Italian researcher and manufacturer Probiotical, the company says it has the ability to begin and scale production of Biome Acne Probiotcal quickly.
The product is expected to launch in Q4 FY22 and will reportedly become one of the world’s first clinically proven probiotics for the management of acne.
Biome Acne Probiotic will become available to over 2300 community pharmacies and independent health practitioners across Australia, and will also be launched into the UK and New Zealand markets as “Biome Derma”.
In afternoon trade, shares have been trading 5 per cent higher at 10 cents at 2.45 pm AEDT.